Revolution Medicines will release Q1 2025 financial results on May 7, followed by a management webcast.
Quiver AI Summary
Revolution Medicines, Inc. announced that it will release its financial results for the first quarter of 2025 on May 7, 2025, after the market closes. Following the announcement, the senior management team will conduct a webcast at 4:30 p.m. ET to discuss the financial outcomes and provide corporate updates, with a replay available for two weeks. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, featuring a pipeline that includes multiple RAS(ON) inhibitors currently in clinical development, such as daraxonrasib and elironrasib. They also anticipate advancing RMC-5127, a G12V-selective inhibitor, into clinical trials, alongside other mutant-selective inhibitors in their research and development pipeline.
Potential Positives
- The upcoming webcast on May 7, 2025, provides shareholders and interested parties an opportunity to hear directly from senior management about the company’s financial results and corporate progress.
- The development of RAS(ON) inhibitors positions Revolution Medicines uniquely in the oncology market, focusing on targeted therapies for RAS-addicted cancers, which could address significant medical needs.
- Revolution Medicines has a robust R&D pipeline, showcasing a commitment to innovation with multiple candidates currently in clinical development.
- The anticipation of RMC-5127, a new G12V-selective inhibitor entering clinical development, indicates ongoing growth and potential advancements in the company’s therapeutic offerings.
Potential Negatives
- The timing of the financial results announcement is close to the end of the first quarter, which may indicate that the company's financial performance may not have met expectations, potentially raising concerns among investors.
- The press release does not provide any information about the current status or success of the company's ongoing clinical trials, which could be seen as a lack of transparency regarding their R&D progress.
- The absence of concrete updates on product advancements or regulatory progress may suggest stagnation in the company's pipeline, potentially impacting investor confidence.
FAQ
When will Revolution Medicines report its first quarter 2025 financial results?
Revolution Medicines will report its first quarter 2025 financial results on May 7, 2025, after market close.
What time is the webcast for Revolution Medicines' financial results?
The webcast will take place at 4:30 p.m. ET on May 7, 2025.
How can I access the webcast for Revolution Medicines' earnings call?
To access the webcast, visit https://ir.revmed.com/events-and-presentations.
What are Revolution Medicines' main products in development?
Revolution Medicines is developing RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib.
Where can I find more information about Revolution Medicines?
Visit www.revmed.com for more information and follow them on LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RVMD Insider Trading Activity
$RVMD insiders have traded $RVMD stock on the open market 23 times in the past 6 months. Of those trades, 2 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:
- THILO SCHROEDER has made 2 purchases buying 1,304,347 shares for an estimated $59,999,962 and 0 sales.
- MARK A GOLDSMITH (See Remarks) has made 0 purchases and 6 sales selling 93,452 shares for an estimated $4,868,888.
- STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 4 sales selling 24,623 shares for an estimated $1,317,825.
- JEFF CISLINI (General Counsel) has made 0 purchases and 6 sales selling 16,058 shares for an estimated $806,784.
- MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 2 sales selling 7,387 shares for an estimated $315,938.
- SUSHIL PATEL sold 5,000 shares for an estimated $270,714
- JACK ANDERS (Chief Financial Officer) has made 0 purchases and 2 sales selling 4,499 shares for an estimated $192,410.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RVMD Hedge Fund Activity
We have seen 164 institutional investors add shares of $RVMD stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,346,755 shares (+54.5%) to their portfolio in Q4 2024, for an estimated $146,387,063
- VANGUARD GROUP INC added 2,185,082 shares (+14.7%) to their portfolio in Q4 2024, for an estimated $95,575,486
- FARALLON CAPITAL MANAGEMENT LLC added 1,931,000 shares (+17.1%) to their portfolio in Q4 2024, for an estimated $84,461,940
- NEXTECH INVEST LTD. added 1,304,347 shares (+20.7%) to their portfolio in Q4 2024, for an estimated $57,052,137
- PARADIGM BIOCAPITAL ADVISORS LP added 1,239,022 shares (+23.3%) to their portfolio in Q4 2024, for an estimated $54,194,822
- FMR LLC added 866,190 shares (+14.7%) to their portfolio in Q4 2024, for an estimated $37,887,150
- BLACKROCK, INC. added 852,690 shares (+6.1%) to their portfolio in Q4 2024, for an estimated $37,296,660
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RVMD Analyst Ratings
Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/08/2025
To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.
$RVMD Price Targets
Multiple analysts have issued price targets for $RVMD recently. We have seen 4 analysts offer price targets for $RVMD in the last 6 months, with a median target of $67.0.
Here are some recent targets:
- Benjamin Burnett from Stifel Nicolaus set a target price of $64.0 on 04/01/2025
- Eliana Merle from UBS set a target price of $71.0 on 01/08/2025
- Joseph Catanzaro from Piper Sandler set a target price of $70.0 on 11/07/2024
- Raghuram Selvaraju from H.C. Wainwright set a target price of $62.0 on 11/04/2024
Full Release
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations . Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit
www.revmed.com
and follow us on
LinkedIn
.
Revolution Medicines Media & Investor Contact:
[email protected]
[email protected]
